Treatment provides women with a uterus-preserving, incision-free, outpatient option with significant symptom relief and fast recovery Redwood City, October 27, 2020 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine
Gynesonics Announces Publication of Long Term Three-Year Results of the SONATA FDA IDE Pivotal Trial
Outcomes Demonstrate Significant and Sustained Symptom Relief, High Patient Satisfaction, Improved Quality of Life and Low Reintervention Rates Redwood City, CA, October 13, 2020 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic
Gynesonics Introduces Sonata in Prominent New York City Fibroid Center
Sonata System Offers Innovative Incision-Free Fibroid Treatment Option For Women Suffering from Symptomatic Uterine Fibroids Redwood City, Calif., September 22, 2020 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine
Gynesonics Announces Brigham and Women’s Faulkner Hospital Becomes the First in Massachusetts to Offer Innovative New Procedure to Treat Symptomatic Uterine Fibroids
Sonata Treatment provides patients with an incision-free, outpatient option with exceptional results and fast recovery Redwood City, Calif. – September 3, 2020 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids,
Gynesonics Announces Publication of OPEN Clinical Trial Results, Demonstrating No Intrauterine Adhesion Formation Following Treatment with the Sonata System
Clinical Study Demonstrates No Adhesion Formation at Second-Look Hysteroscopy Performed Six Weeks After Transcervical Fibroid Ablation with the Sonata System Redwood City, Calif. – August 20, 2020 – Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions
Medical Device Executive Nelson Whistance Joins Gynesonics as Vice President of U.S. Sales
Redwood City, CA – August 17, 2020 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that medical device executive Nelson Whistance has been named Vice President of U.S. Sales. Mr. Whistance
Gynesonics Announces Rapid Expansion In Positive Payer Coverage for Sonata
More Than 50 Million Covered Lives Added in First 6 Months of 2020 Redwood City, CA, July 20, 2020 — Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that health insurance coverage of more than 50
Gynesonics Announces Publication of CHOICES: A Comparative Study of the Sonata Treatment Versus Myomectomy
Sonata Demonstrates Significant Advantages in Reducing Procedure Time, Length of Stay and Procedure Related Costs Compared to Myomectomy Redwood City, CA, June 30, 2020 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine